Our Pipeline

Proprietary pipeline

We develop innovative therapeutics aimed at improving the lives of cancer patients. We have built a robust pipeline leveraging our small molecule expertise in targeted protein degradation, immuno-oncology, precision oncology, and epigenetics

Development stage
Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

AUR-101
RORgt inverse agonist

AUR-101, RORgt inverse agonist

Stage – Clinical Phase 2B

AUR-101 is an oral, small molecule RORgt inverse agonist. It is the most advanced clinical asset in this class, being developed for the treatment of moderate to severe psoriasis.

Global

Psoriasis, Psoriatic arthritis, Ankylosing spondylitis

CA-170
Dual inhibitor of PDL1 and VISTA#

CA-170, Dual inhibitor of PDL1 and VISTA

Stage – Clinical Phase 3

CA-170 is an oral, small molecule dual inhibitor of PDL1 and VISTA. In contrast to antibodies, CA-170 offers the advantages of ease of dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

Asia

NSCLC, bladder & kidney cancers

AUR-109
Spectrum selective kinase inhibitor

AUR-109, Spectrum selective kinase inhibitor

Stage – Clinical Phase 2A

AUR-109 (formerly known as ODM-203) is an oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2 along with clinically validated targets FGFRs and VEGFRs. It is currently being evaluated in FGFR mutant bladder cancer. The unique selectivity profile allows potential expansion of indications.

Global

Cancers of bladder, lung, breast, ovary, kidney, liver & lung fibrosis

AUR-108
DHODH inhibitor

AUR-108, DHODH inhibitor

Stage – Clinical Phase 1

AUR-108 (formerly known as AG-636) is an oral, potent DHODH inhibitor with high selectivity against a panel of dehydrogenases. It has broad activity in pre-clinical models of lymphoma and leukemia, with a potential for combination with standard of care.

Global

Leukaemia and lymphoma

AUR-103
CD47 antagonist*

AUR-103, CD47 antagonist

Stage – Clinical Phase 1

AU-103 is a highly differentiated oral small molecule inhibitor of CD47. In pre-clinical studies, AUR-103 does not show hemotoxicity. This is in contrast to anti-CD47 antibodies, where significant dose-limiting toxicities of anemia, thrombocytopenia, and leukopenia have been observed.

Global

Leukaemia, lymphoma and multiple solid tumors

AUR-105
PRMT5 inhibitor

AUR-105, PRMT5 inhibitor

Stage – Clinical Phase 1

A substrate competitive inhibitor of PRMT5, with a high tumor/plasma ratio in xenograft studies. AU-105 has demonstrated significant efficacy in multiple pre-clinical cancer models.

Global

Leukaemia, lymphoma and multiple solid tumors

AUR-106
Dual inhibitor of TIGIT and PDL1

AUR-106, Dual inhibitor of TIGIT and PDL1

Stage – Clinical Phase 1

An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR-106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

Global

Multiple cancers

Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

AUR-107
CBP/p300 inhibitor

AUR-107, CBP/p300 inhibitor

Stage – IND-enabling

AUR-107 is an oral, dual inhibitor of CBP and p300 with excellent selectivity against other bromodomain containing proteins. The molecule has demonstrated excellent efficacy in pre-clinical models with good therapeutic margins.

Global

NSCLC, lymphomas, leukemias, bladder cancers and prostate cancers

Program
MOA
Rights
Indications
Discovery
Pre-clinical
IND-enabling
Clinical Phase I
Clinical Phase II
Clinical Phase III

SMARCA 2/4
dual

Global

Prostate cancer, leukemia, lymphoma and myeloma

Selective SMARCA2*

Global

SMARCA-4 mutant lung cancers, medulloblastoma; and Burkitt's lymphoma

CBP/p300 degrader

Global

Breast and prostate cancers

CD73-A2AR dual

Global

Multiple cancers

* Aurigene will be advancing these programs till marketing approval

# Co-development programs with Aurigene leading clinical trials in India

Partnered Programs in Clinic

Here are the key compounds discovered at Aurigene in clinical development.

Partner
Target & Compound
Pre-clinical
Clinical Phase I
Clinical Phase II
Clinical Phase III

Novartis
(licensed to Laekna)

CYP17, CFG920

Orion

BET, ODM 207

Astellas

PPARδ modulator, MA2011

PPARδ modulator, MTB2

Asana Biosciences

SYK/JAK, ASN002

BRAK/PI3K, ASN003

Japanese Pharma

Not disclosed

H3 Biomedicine

ESR1, H3B-6545

Curis

PD- L1/VISTA, CA170

IRAK4, CA4948

Exelixis

CDK7, XL102

FABP5, XL114

licensed/co-development programs